A phase 2 study of BMN-349
Latest Information Update: 08 Oct 2025
At a glance
- Drugs BMN 349 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Therapeutic Use
Most Recent Events
- 08 Oct 2025 This Phase 2 study expected to begin in the first half of 2026